Ohio State’s tight end Nick Lautar is fascinating. He doesn’t have the background of a basketball player like almost all other tight ends, but rather, he was a wrestler. The Buckeyes may have an elite ...
National Signing Day is in the rearview, and Rivals is looking back at the 2026 class beginning with the nation’s top ...
KOMZIFTI (ziftomenib), the first and only once-daily oral menin inhibitor for adult patients with R/R AML with a susceptible NPM1 mutation who have no satisfactory alternative treatment options, has ...
Genetix Biotherapeutics Inc. today announced real-world data from the commercial implementation of ZYNTEGLOtm and LYFGENIAtm, first-in-class ex vivo gene addition therapies for the treatment of ...
The Seattle Seahawks aren't letting their shortcomings get in their way, as they've now won seven of their last eight games.
Mo Salah will not find a whole lot of sympathy for his big old tantrum, which has given Arne Slot to punish him as he sees ...
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 8, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company developing CID-103, a potentially best-in-cl ...
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects ...
Panasonic Holdings Corporation ( PCRHY) Analyst/Investor Day December 1, 2025 7:00 PM EST ...
Eli Lilly and Company today announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results